Aligos Therapeutics (ALGS) Operating Income (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Operating Income came in at -$26.9 million in Q1 2026, down 39.94% YoY from -$44.8 million in Q1 2025, and down 23.45% on a QoQ basis from -$21.8 million in Q4 2025.
Aligos Therapeutics (ALGS) Operating Income (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Operating Income data on file, last reported at -$26.9 million in Q1 2026.
- Quarterly Operating Income fell 39.94% year-over-year to -$26.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$95.7 million (down 10.79% YoY) and the FY2025 annual result came in at -$88.0 million, up 1.31% from the prior year.
- Operating Income slipped to -$26.9 million in Q1 2026, from -$21.8 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$18.6 million in Q2 2025 to a low of -$35.6 million in Q1 2022.
- A 5-year average of -$22.9 million and a median of -$21.8 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income soared 42.7% — and 2025, when it sank 40.88%.
- Tracing ALGS's Operating Income over 5 years: stood at -$22.7 million in 2022, then fell by 14.62% to -$26.0 million in 2023, then increased by 20.9% to -$20.6 million in 2024, then slipped by 6.08% to -$21.8 million in 2025, then dropped by 23.45% to -$26.9 million in 2026.
- The last three Operating Income figures came in at -$26.9 million (Q1 2026), -$21.8 million (Q4 2025), and -$28.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | -1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.89 Mn |
| Mar 31, 2026 | -26.93 Mn |
| Dec 31, 2025 | -21.81 Mn |
| Sep 30, 2025 | -28.36 Mn |
| Jun 30, 2025 | -18.57 Mn |
| Mar 31, 2025 | -19.24 Mn |
| Dec 31, 2024 | -20.56 Mn |
| Sep 30, 2024 | -20.13 Mn |
| Jun 30, 2024 | -26.41 Mn |
| Mar 31, 2024 | -22.05 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Sep 30, 2023 | -19.07 Mn |
| Jun 30, 2023 | -19.14 Mn |
| Mar 31, 2023 | -23.92 Mn |
| Dec 31, 2022 | -22.68 Mn |
| Sep 30, 2022 | -18.95 Mn |
| Jun 30, 2022 | -20.39 Mn |
| Mar 31, 2022 | -35.56 Mn |
| Dec 31, 2021 | -37.95 Mn |
| Sep 30, 2021 | -33.07 Mn |